SELECTIVE IL-23 INHIBITION BY RISANKIZUMAB MODULATES THE MOLECULAR PROFILE IN THE COLON OF ACTIVE CROHN?S DISEASE PATIENTS

Patrick Baum  1     Richard Vinisko  2     Ramona Schmid  1     Wulf Boecher  3     Steven J Padula  4     Azucena Salas     Jay S Fine     Julian PanĂ©s     Sudha Visvanathan    
1 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
2 Boehringer Ingelheim Pharmaceuticals Inc., N/A, Ridgefield, United States of America
3 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
4 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingel

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing